SS
CLDX icon

SBI Securities’s Celldex Therapeutics CLDX Stock Holding History

SBI Securities’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$670 Hold
18
– – ﹤0.01% 2937
2026
Q1 		$571 Sell
18
-1
-5% -$27 ﹤0.01% 2841
2025
Q4 		$516 Sell
19
-30
-61% -$790 ﹤0.01% 2867
2025
Q3 		$1.27K Buy
49
+3
+7% +$70 ﹤0.01% 2593
2025
Q2 		$936 Hold
46
– – ﹤0.01% 2708
2025
Q1 		$835 Buy
46
+16
+53% +$357 ﹤0.01% 2656
2024
Q4 		$758 Buy
+30
New +$815 ﹤0.01% 2734

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SBI Securities's CLDX Position: Q2 2026 in Review

SBI Securities held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 18 shares worth $670. The position accounts for ﹤0.01% of the portfolio, ranked #2937.

SBI Securities first reported a position in CLDX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.27K in Q3 2025. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • SBI Securities held 18 shares of Celldex Therapeutics worth $670 as of Q2 2026.
  • SBI Securities left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2937 holding.
  • SBI Securities first reported a position in Celldex Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Celldex Therapeutics position peaked at $1.27K in Q3 2025.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.